|
Non-Small Cell Lung Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Nevertheless, the role of KRAS oncogene in non-small-cell lung cancer remains unclear.
|
23524403 |
2013 |
|
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In this study, we investigated the effect of combining lovastatin with gefitinib on gefitinib-resistant human non-small cell lung cancer (NSCLC) cell lines with K-Ras mutations.
|
19760159 |
2010 |
|
Non-Small Cell Lung Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In a panel of KRAS(M) and KRAS(WT) NSCLC cell lines, we determined growth inhibition (GI) following maximal reduction in p-ERK and p-S6RP caused by trametinib (MEK inhibitor) and AZD2014 (m-TOR inhibitor), respectively.
|
27441499 |
2016 |
|
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Patients with non-small cell lung cancer who have KRAS mutations do not respond to tyrosine kinase inhibitors; therefore, accurate detection of KRAS mutations is important for deciding therapeutic strategies.
|
20007840 |
2010 |
|
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors.
|
20592359 |
2010 |
|
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In a retrospective analysis of the prevalence of KRAS mutations in patients with advanced non-small cell lung cancer (NSCLC), we detected a unique and not earlier described case of a double combination of mutations at codons 12 and 13 of the KRAS gene in a patient with lung adenocarcinoma.
|
23729630 |
2013 |
|
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
TP53, EGFR and KRAS mutations were found in NSCLC with no link with asbestos exposure.NF2 was only altered in MPM.
|
23435014 |
2013 |
|
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In order to rigorously analyze the amount of cfDNA needed, we constructed 72 athymic nude mice xenografted with NCI-H1975 (harboring a EGFR T790M mutation) or NCI-H460 (harboring a KRAS Q61H mutation) human NSCLC.
|
29497175 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
KRAS mutations and WT1 (cMyc) expression were detected using Sanger sequencing and real-time PCR in 77 patients with non-small cell lung cancer (NSCLC).
|
25613309 |
2015 |
|
Non-Small Cell Lung Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
This phase 2 trial (ClinicalTrials.gov identifier NCT00548093) assessed the efficacy, safety, and impact on health-related quality of life of dacomitinib (PF-00299804), an irreversible tyrosine kinase inhibitor (TKI) of human epidermal growth factor receptors (EGFR)/HER1, HER2, and HER4, in patients with KRAS wild-type non-small cell lung cancer (NSCLC).
|
24501009 |
2014 |
|
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
To assess the association between CT features and EGFR, ALK, KRAS mutations in non-small cell lung cancer.
|
25956936 |
2016 |
|
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
K-RAS was mutated in 12.2% of NSCLC tumours, the majority of the mutations being found in ADC (adenocarcinoma, 27.0%).
|
18957720 |
2008 |
|
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our study indicates that the detection of the KRAS and p53 mutations in BAL fluids could be a helpful addition to cytology and histology examination for the diagnosis of peripheral NSCLC.
|
24519547 |
2014 |
|
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
KRAS mutation should be included as indicator of resistance in the panel of markers used to predict response to EGFR-TKIs in NSCLC.
|
17504988 |
2007 |
|
Non-Small Cell Lung Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The addition of cetuximab to chemotherapy improved survival in the first-line treatment of recurrent/metastatic SCCHN and KRAS wild-type mCRC regardless of tumour EGFR expression level, indicating that in contrast to findings in NSCLC, EGFR expression level is not a clinically useful predictive biomarker in these settings.
|
23265711 |
2013 |
|
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Patients with KRAS-mutant advanced NSCLC demonstrated a significantly shorter progression-free survival in response to first line chemotherapy (4.5 months versus 5.7 months, p=0.008) compared to pan-mutation negative patients.
|
26775593 |
2016 |
|
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The present study explored the association between <i>KRAS proto-oncogene GTPase (KRAS), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α (PIK3CA) and tumor protein p53 (TP53) mutations, and the clinical features and survival prognosis in 50 patients with non-small cell lung cancer (NSCLC).
|
30867754 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our aim was to study the association between the presence of KRAS mutations at codon 12 and several clinical variables in advanced non-small cell lung cancer (NSCLC) patients.
|
21074889 |
2011 |
|
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
KRAS mutations detected in ctDNA predict a worse PFS (HR=1.83, 95% CI 1.40-2.40, p<0.0001) and OS (HR=2.07, 95% CI 1.54-2.78, p<0.00001) in advanced NSCLC patients treated by chemotherapy.
|
28430611 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Dual inhibition of the HSP90 and PI3K signaling pathways with sub-therapeutic doses of these combined anticancer drugs may represent a potent treatment strategy for KRAS-mutant NSCLC with intrinsic resistance to PI3K inhibition.
|
28797845 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
EGFR and KRAS mutations and altered c-Met gene copy numbers in primary non-small cell lung cancer and associated stage N2 lymph node-metastasis.
|
21982684 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Six (24 %) NSCLCs showed KRAS mutations (three ACC, three SCC), 5 codon 12 mutations (G>T, T>C, G>A) and one codon 13 mutation (G>T).
|
24973952 |
2014 |
|
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Dominant oncogenes of the Myc family are frequently overexpressed in both SCLC and non-small cell lung cancer (NSCLC), while the K-RAS oncogene is never mutated in SCLC but it is in 30% of NSCLCs.
|
11479891 |
2001 |
|
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The mutations in exon 2 of KRAS, exon 18 of DDR2, and exons 5-6 of TP53 genes were screened in lung cancer samples, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) using PCR and sequencing techniques.
|
30048458 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Evaluation of Kras gene mutation and copy number gain in non-small cell lung cancer.
|
21150464 |
2011 |